Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of HSRx431 for the treatment of Zika virus

Trial Profile

A study of HSRx431 for the treatment of Zika virus

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs HSRx 431 (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Sep 2016 New trial record
    • 06 Sep 2016 According to a HSRx Biopharmaceutical media release, this trial anticipated in the early 2017.

Trial Overview

Purpose

This phase I study will investigate the safety of HSRx431 for the treatment of Zika virus

Diseases Treated

Indication Qualifiers Patient Segments
Zika virus infection treatment -

Subjects

  • Subject Type patients
  • Sex male & female
  • Age Group adult

Patient Inclusion Criteria

patients infected with Zika virus

Trial Details

Organisations

  • Affiliations HSRx Biopharmaceutical

Trial Dates

  • Initiation Dates

    Planned : 01 Aug 2017

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
HSRx 431Primary Drug
-
-

HSRx431

Trial History

Event Date Event Type Comment
23 Sep 2016 New trial record New trial record Updated 23 Sep 2016
06 Sep 2016 Other trial event According to a HSRx Biopharmaceutical media release, this trial anticipated in the early 2017. Updated 24 Sep 2016

References

  1. HSRx Biopharmaceutical. Broad-Spectrum Antiviral Drug HSRx 431(Tm) Tests Effective Against Zika Virus. Media-Rel 2016;.

    Media Release
Back to top